Market narrative

Read the headlines around the signals.

Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.

Latest zacks.com · about 13 hours ago

Here's Why Park National (PRK) is a Great Momentum Stock to Buy

Does Park National (PRK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Stocks

More recent coverage

Page 90
SNN globenewswire.com · about 13 hours ago

Smith+Nephew celebrates mobility, recovery and football's greatest traditions during Pro Football Hall of Fame Enshrinement Week

Canton, Ohio—As thousands of football fans descend on Canton for the 2026 Pro Football Hall of Fame Enshrinement Week, Smith+Nephew, the Global medical technology company, will join the celebration with a series of engagement activities highlighting the connection between movement, recovery and the enduring spirit of the game. Smith+Nephew is the official Joint Replacement and Sports Medicine Technology Partner of the Pro Football Hall of Fame.

FOX newsfilecorp.com · about 13 hours ago

Kaplan Fox Encourages GPGI, Inc. (GPGI) Investors with Losses to Contact the Firm Before September 14, 2026

New York, New York--(Newsfile Corp. - August 5, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against GPGI, Inc. f/k/a CompoSecure, Inc. (NYSE: GPGI) (NYSE: CMPO) on behalf of investors that purchased or otherwise acquired GPGI Class A common stock between November 3, 2025 and May 6, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in GPGI and have suffered losses, you may CLICK HERE to contact us.

globenewswire.com · about 13 hours ago

Chronic Urticaria Clinical Trial Landscape Becomes Increasingly Crowded with 20+ Pharma Companies | DelveInsight

New York, USA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Chronic Urticaria Clinical Trial Landscape Becomes Increasingly Crowded with 20Pharma Companies | DelveInsight The chronic urticaria clinical trial analysis report delivers important insights into ongoing research of 30pipeline chronic urticaria drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

QNME globenewswire.com · about 13 hours ago

Quanome Technologies, Inc. Launches New Corporate Identity and Expands Strategic Focus Across the Quantum Technology Landscape

Common Stock Begins Trading on the Nasdaq Capital Market Under "QNME" ITASCA, Ill. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Quanome Technologies, Inc. (formerly Lakeside Holding Limited) (Nasdaq: QNME, "Quanome" or the "Company") today announced that its common stock began trading on the Nasdaq Capital Market under its new corporate name and updated ticker symbol, "QNME.

← Newer
Older →